Adma Biologics (ADMA) Accumulated Expenses (2011 - 2026)
Adma Biologics' (ADMA) quarterly Accumulated Expenses came in at $172000.0 in Q4 2025, down 99.5% YoY from $34.1 million in Q4 2024, and down 96.19% on a QoQ basis from $4.5 million in Q3 2025.
Adma Biologics (ADMA) Accumulated Expenses (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Accumulated Expenses data on file, last reported at $172000.0 in Q4 2025.
- Quarterly Accumulated Expenses fell 99.5% year-over-year to $172000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $172000.0 (down 99.5% YoY) and the FY2025 annual result came in at $172000.0, down 99.5% from the prior year.
- Accumulated Expenses retreated to $172000.0 in Q4 2025, from $4.5 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $34.1 million in Q4 2024 to a low of $172000.0 in Q4 2025.
- A 5-year average of $9.1 million and a median of $3.8 million in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2021 — Accumulated Expenses jumped 2242.26% — and 2025, when it plunged 99.5%.
- Tracing ADMA's Accumulated Expenses over 5 years: stood at $17.2 million in 2021, then plunged by 75.64% to $4.2 million in 2022, then soared by 684.91% to $32.9 million in 2023, then climbed by 3.6% to $34.1 million in 2024, then sank by 99.5% to $172000.0 in 2025.
- The last three Accumulated Expenses figures came in at $172000.0 (Q4 2025), $4.5 million (Q3 2025), and $3.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.11 Mn |
| Dec 31, 2025 | 172,000.00 |
| Sep 30, 2025 | 4.51 Mn |
| Jun 30, 2025 | 3.07 Mn |
| Mar 31, 2025 | 1.89 Mn |
| Dec 31, 2024 | 34.11 Mn |
| Sep 30, 2024 | 2.01 Mn |
| Jun 30, 2024 | 12.60 Mn |
| Mar 31, 2024 | 1.22 Mn |
| Dec 31, 2023 | 32.92 Mn |
| Sep 30, 2023 | 3.31 Mn |
| Jun 30, 2023 | 2.20 Mn |
| Mar 31, 2023 | 1.75 Mn |
| Dec 31, 2022 | 4.19 Mn |
| Sep 30, 2022 | 18.38 Mn |
| Jun 30, 2022 | 15.96 Mn |
| Mar 31, 2022 | 1.57 Mn |
| Dec 31, 2021 | 17.21 Mn |
| Sep 30, 2021 | 14.41 Mn |
| Jun 30, 2021 | 1.54 Mn |